Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of tiroid saratoni.
Eisai, Lenvima tiroid bezining rezektsiya qilinmagan saratonini klinik davolash uchun yangi standart bo'lishini aytdi. Sanoat Lenvima haqida juda optimistik va bu dori Eisai uchun yangi pul sigiriga aylanishi kutilmoqda, uning yillik savdosi 1 milliard dollardan oshadi.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved shish volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
Hozirgi vaqtda qalqonsimon bez saratonining ko'p turlarini davolash mumkin bo'lsa-da, yomonlashgandan keyin davolash uchun bir nechta variant mavjud. Differentsial qalqonsimon saraton (DTC) qalqonsimon bezning eng keng tarqalgan xavfli o'smasi bo'lib, so'nggi yillarda uning tarqalishi doimiy ravishda oshib bormoqda.
Lenvatinib - yangi bog'lanish rejimiga ega bo'lgan og'iz orqali qabul qilinadigan ko'p retseptorli tirozin kinaz (RTK) inhibitori. O'simta proliferatsiyasi va onkogen signalizatsiya yo'llari bilan bog'liq bo'lgan boshqa RTKlarni inhibe qilishdan tashqari, qon tomir endotelial o'sish omili (VEGF) retseptorlari kinaz faolligini tanlab inhibe qilishi mumkin.
